BY THE OPTIMIST DAILY EDITORIAL TEAM
Most Alzheimer’s research goes after the toxic proteins directly. This study asks a different question: what if the brain’s own clearing system could be fixed instead?
Research from Monash University’s Institute of Pharmaceutical Sciences, published in ACS Chemical Neuroscience, found that a copper compound called Cu(ATSM) repaired a waste-clearing mechanism at the blood-brain barrier, letting the brain flush amyloid-beta proteins out on its own.
Why the blood-brain barrier matters
The brain actively pumps out its own waste. Molecular pumps called P-glycoprotein, or P-gp, line the blood-brain barrier and push amyloid-beta into the bloodstream where it can be cleared. In Alzheimer’s, those pumps weaken progressively, the proteins accumulate, and over time the damage to memory follows.
The Monash team treated an Alzheimer’s mouse model with Cu(ATSM) for 56 days. P-gp pump abundance rose 24.1 percent. Toxic amyloid-beta dropped 42 percent. Spatial learning improved by nearly 44 percent.
“By improving the pumps, the brain can finally clear out the trapped waste,” said lead author Dr. Jae Pyun, who completed this work as the final chapter of his PhD. “This is the first study to show that Cu(ATSM) can increase the abundance of P-gp clearance pumps in an Alzheimer’s model.”
Why this compound is closer to patients than most
Most promising Alzheimer’s lab results don’t make it to human trials quickly. Cu(ATSM) has an unusual advantage: it has already been tested in humans for Parkinson’s disease and ALS, which means a significant portion of early safety evaluation is already behind it.
“Cu(ATSM) has already progressed to clinical testing for conditions like Parkinson’s and ALS,” said senior author Professor Joseph Nicolazzo of Monash. “Because reducing amyloid burden is clinically proven to improve functional outcomes, these preclinical results strongly support the rationale for testing this drug in early symptomatic Alzheimer’s disease.”
What’s still unknown
The team doesn’t yet have a full picture of how proteins leave the brain once the pumps are working again. They suspect Cu(ATSM) may also activate microglia, the brain’s own immune cells, to break down plaques from the inside. The next studies will map the exact clearance routes.
Alzheimer’s recently became Australia’s leading cause of death, passing coronary heart disease, and ranks among the top causes of mortality globally. The field has spent decades trying to eliminate plaques after they form. This study is a case for addressing an earlier failure: the system that was supposed to stop them building up in the first place.
Source study: ACS Chemical Neuroscience– Cu(ATSM) Restores Blood–Brain Barrier Abundance of P-Glycoprotein and Improves Cognitive Function in the APP/PS1 Mouse Model of Alzheimer’s Disease
Did this solution stand out? Share it with a friend or support our mission by becoming an Emissary.
